-YUTIQ ™ approved by U.S. FDA ; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ technology for posterior segment uveitis in Greater China - -Commercial preparations

WATERTOWN, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the

WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter of fiscal year 2019 on Tuesday, November 6 .

- Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

WATERTOWN, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data supporting the

- Five oral abstracts to be presented at annual meeting and subspecialty days – -24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company

- The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S.  - Company to host conference call today at 8:30 a.m. ET WATERTOWN, Mass. , Oct.

WATERTOWN, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of calendar year 2019 -Balance sheet strengthened by $35 million of capital led by EW

WATERTOWN, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its

WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved

WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal 2018 fourth quarter and full year on Wednesday,

WATERTOWN, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled

- Senior Pharmaceutical Industry Executive with Extensive Experience Leading Regulatory Affairs - WATERTOWN, Mass. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative

WATERTOWN, Mass. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to David Price , EyePoint’s newly

WATERTOWN, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that David Price , Chief Financial Officer, is scheduled to present an

Seasoned financial executive brings more than 25 years of diverse financial and operational experience WATERTOWN, Mass. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative

YUTIQ ™ delivers positive twelve month efficacy vs sham with reduced rates of recurrence and reduced use of rescue therapies in patients with noninfectious posterior segment uveitis NDA currently under review by FDA ; PDUFA action date of November 5, 2018 WATERTOWN, Mass.

WATERTOWN, Mass. , July 11, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ™ (fluocinolone

WATERTOWN, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr.